Navigation Links
Transgenomic, Inc. Executes License Option agreement for Parkinson's Disease Diagnostic Markers with Gene Solutions, LLC
Date:12/17/2009

OMAHA, Neb., Dec. 17 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) announced today that it has reached agreement with Gene Solutions for an exclusive licensing option to a set of validated mutations found in Parkinson's disease patients that can form the basis of a novel and accurate diagnostic test for Parkinson's disease. Transgenomic's platform mitochondrial mutation detection technology will be evaluated and optimized to develop a diagnostic test that evaluates and quantitates the presence of low-level mitochondrial DNA (mtDNA) variants. These mutations have been demonstrated to be present in Parkinson's disease patients but rarely in age-matched control individuals.

Parkinson's disease is a devastating neurological disorder affecting at least 1 million diagnosed patients and potentially another 3-4 million undiagnosed patients in the US alone. Symptoms can be modified to some degree by early intervention and treatment with dopamine or other neurological enhancing agents. The earlier the diagnosis, the better the long-term outcome can be for the sufferers of this disease. But often the disease has progressed significantly before a diagnosis can be accurately made and treatment initiated.

Each cell in the body has hundreds to thousands of mitochondria, organelles that produce the energy required for cells to function normally. Mitochondria contain their own genome that encodes many of the proteins necessary to perform cellular energy production. Damaged or mutated mitochondrial DNA (mtDNA) leads to cellular metabolism disorders by interfering with energy production. A large body of research conducted over the past twenty years has implicated mitochondrial abnormalities in certain neurodegenerative diseases including Parkinson's disease. Gene Solutions has discovered a specific region of mtDNA in which variants in the genetic sequence are present in Parkinson's patients. These variants are prese
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
5. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
6. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
7. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
8. Lilly and Glenmark Pharmaceuticals Announce License Agreement
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
11. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... AMSTERDAM , July 25, 2014 ... America is returning for the seventh year to São ... to 7 th August 2014. The event will co-locate ... America,s most comprehensive meeting point for the pharmaceutical ... the top 25 countries for pharmaceutical sales are now exploring ...
(Date:7/24/2014)... 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... date for Zalviso remains July 27, 2014.  ... stating the Food and Drug Administration (FDA) had approved ... no notification to the company from the FDA regarding ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... , Weltweite Exklusivlizenz ... ermöglicht QIAGEN die Entwicklung von Tests auf ... Blutkrebs  Neuer Test weist Mutationen ... Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
(Date:7/25/2014)... NY (PRWEB) July 25, 2014 ... prices across the board for the Guinness International Champions ... and Olympiacos FC at Soldier Field on Sunday, ... offering their customer appreciation promo/coupon/offer code SOCCER-2014 for added ... amazing year for diehard soccer fans in North America. ...
(Date:7/25/2014)... (HealthDay News) -- Seniors are more easily distracted during ... study finds. "Almost any type of memory test ... of 25 on," study co-author Randi Martin, professor of ... release. However, Martin said, this study shows that ... older adults compared with younger adults. The study ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Sport ... for the recent Nike National Invitational Tournament (NIT) ... United States Junior National Tournament (USJN) in ... , The flooring for these prestigious national tournaments included ... 300,000 square feet of playing surface at McCormick Place ...
(Date:7/25/2014)... Reproductive Science Center (RSC) of New England ... Lead Physician at RSC Rhode Island, received the distinguished ... fertility care and community outreach issued by Providence Business ... Awards ceremony held July 24th at Salve Regina University ... regarded, emerging leaders in their field were recognized by ...
(Date:7/25/2014)... 25, 2014 Florida Hospital and MOSI officially ... organizations for years to come and make a difference in ... $2 million dollar check to provide the support needed to ... enable MOSI to transform the IMAX Dome Theatre from film ... the only IMAX Dome Theatre in the state of Florida, ...
Breaking Medicine News(10 mins):Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Distractions Seem More Troublesome With Age 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4
... may be associated with an increased ability to taste. For ... skip breakfast. The men had not eaten since 6:30 p.m. ... or bitter solutions and describe the flavor they tasted. The ... out after tasting them. One hour after lunch, the men ...
... with chemo-resistant leukemia, a new drug is showing promising ... experimenting with bacteria-based recombinant immunotoxins. An immunotoxin is bioengineered ... part of the antibodies that are commonly used to ... encouraging results in a phase II study. ,Researchers ...
... vaccine loses some of its effectiveness in the ... vaccinate their children against chickenpox between 12 months ... further investigate the vaccine after chickenpox outbreaks were ... nearly 350 children ages 13 months or older ...
... the third most common form of cancer in the United ... may provide protection against colon cancer. In addition, soy protein ... develop. ,Investigators fed five different diets to female mice ... designed to compare the effects of specific ingredients. Diet one ...
... up and get moving. Breast cancer survivors who ... esteem and better mood than sedentary breast cancer ... compared 40 women who said they regularly exercised ... survivors. Regular exercisers reported significantly more positive attitudes ...
... have an increased risk of heart disease and death. ... older women who participated in the Women's Health Initiative ... designed to determine how biological and lifestyle factors influence ... health conditions. For this study, participants were evaluated for ...
Cached Medicine News:
... holmium laser combines excellent cutting, ablation ... bloodless procedures. It is also extremely ... bladder stones of all compositions, making ... Because its laser light is transmitted ...
... new CO2 laser system with intensities up ... an exclusive design for easy handling and ... is the leader in a new generation ... of Dekas laser devices, like safety and ...
... The MedArt® 435 is a full system for ... which makes up a complete hair reduction system. ... ensure sufficient heating of the hair bulb and ... beam is distributed to the tissue through the ...
VERSASTEP™ Reposable Reusable Components (Standard Length)....
Medicine Products: